{"Q": 1, "answer": "no", "rationale": "No intensifier or comparative directly modifies a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_14808", "batch_size": 260, "batch_pos": 14, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment factually describes plans and expectations ('officials said... testing would begin', 'pending results expected') without high-potency framing.", "method": "llm_batch", "batch_id": "batch_2_15340", "batch_size": 260, "batch_pos": 259, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "This discusses future plans ('would begin') and lacks a moderate verb + scale of impact.", "method": "llm_batch", "batch_id": "batch_3_15964", "batch_size": 260, "batch_pos": 200, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_11928", "batch_size": 260, "batch_pos": 194, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment reports factual information about future testing timeline, not a calming cue.", "method": "llm_batch", "batch_id": "batch_5_14700", "batch_size": 260, "batch_pos": 191, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "No minimiser + scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_2460", "batch_size": 260, "batch_pos": 154, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_16796", "batch_size": 260, "batch_pos": 143, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "Describes timeline for future testing ('late-stage testing would begin in 2025') without explicit reassurance.", "method": "llm_batch", "batch_id": "batch_8_6524", "batch_size": 260, "batch_pos": 19, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
